Improve the Rational Design and Translation of Next Generation Small Molecules to Successfully Drug Highly Desirable, Yet Difficult to Reach "Undruggable" Targets
As the renaissance in small molecule drug discovery continues and with over 80% of the proteome waiting to be drugged, the inaugural Proteome- Targeted Drug Discovery Summit 2019 has been founded with the sole purpose to help biopharma drug developers and academic research institutes finally overcome the "undruggable" nature of hard to reach, yet immensely desirable proteome targets.
KEY Features of the Proteome- Targeted Drug Discovery Summit:
World-class speaker faculty from the likes of Amgen, AstraZeneca, Pfizer and Novartis
Curated learning journey from early discovery to clinical development
Critical strategic discussions and case studies focused on the current trends, challenges and opportunities of proteome drug discovery
Intimate networking with key decision-makers from large pharma, biotech and academia through high-quality discussions
"This meeting is set out to explore a particularly exciting area of drug discovery and given the excellent line-up I hope to gather interesting insights, feedback and new ideas that can ultimately move us closer to systematically drugging the undruggable"
Markus Muellner, CTO, PhoreMost Ltd
"I look forward to hear and discuss about novel approaches to well validated and highly desirable yet difficult or undruggable drug targets"
Xin Huang, Head of Structural Biology, Amgen
As the renaissance in small molecule drug discovery continues and with over 80% of the proteome waiting to be drugged, the inaugural Proteome- Targeted Drug Discovery Summit 2019 has been founded with the sole purpose to help biopharma drug developers and academic research institutes finally overcome the "undruggable" nature of hard to reach, yet immensely desirable proteome targets.
KEY Features of the Proteome- Targeted Drug Discovery Summit:
World-class speaker faculty from the likes of Amgen, AstraZeneca, Pfizer and Novartis
Curated learning journey from early discovery to clinical development
Critical strategic discussions and case studies focused on the current trends, challenges and opportunities of proteome drug discovery
Intimate networking with key decision-makers from large pharma, biotech and academia through high-quality discussions
"This meeting is set out to explore a particularly exciting area of drug discovery and given the excellent line-up I hope to gather interesting insights, feedback and new ideas that can ultimately move us closer to systematically drugging the undruggable"
Markus Muellner, CTO, PhoreMost Ltd
"I look forward to hear and discuss about novel approaches to well validated and highly desirable yet difficult or undruggable drug targets"
Xin Huang, Head of Structural Biology, Amgen
